Health regulators in the United States have approved the first pill to treat postpartum depression, offering a lifeline to the as many as one in seven new mothers who suffer from the condition each year. The US Food and Drug Administration (FDA) said on Friday it had approved Zurzuvae, manufactured by Biogen and Sage Therapeutics, for treating severe depression related to childbirth or pregnancy.
